(Q50124375)

25 February 2018

title

Medicare payment policy and recombinant erythropoietin prescribing for dialysis patients. (English)

1 reference

25 February 2018

0 references

1 reference

Powe NR

1

1 reference

25 February 2018

Griffiths RI

2

1 reference

25 February 2018

Anderson GF

3

1 reference

25 February 2018

de Lissovoy G

4

1 reference

25 February 2018

Watson AJ

5

1 reference

25 February 2018

Greer JW

6

1 reference

25 February 2018

Herbert RJ

7

1 reference

25 February 2018

Whelton PK

8

1 reference

25 February 2018

publication date

1 October 1993

1 reference

25 February 2018

American Journal of Kidney Diseases

published in

1 reference

25 February 2018

volume

22

1 reference

25 February 2018

issue

4

1 reference

25 February 2018

page(s)

557-567

1 reference

25 February 2018

Surgical treatment of peptic ulcer in the United States. Trends before and after the introduction of cimetidine

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980929-2

7 January 2021

The effect of the Medicare prospective payment system on the adoption of new technology. The case of cochlear implants

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980929-2

7 January 2021

Changing patterns of hip fracture care before and after implementation of the prospective payment system

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980929-2

7 January 2021

Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980929-2

7 January 2021

Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980929-2

7 January 2021

Biotechnology--the enormous cost of success

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980929-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980929-2

1 reference

7 January 2021

Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980929-2

7 January 2021

Early dosing practices and effectiveness of recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980929-2

7 January 2021

Recombinant human erythropoietin and renal anemia: molecular biology, clinical efficacy, and nervous system effects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980929-2

7 January 2021

Recombinant erythropoietin improves exercise capacity in anemic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980929-2

7 January 2021

Recombinant erythropoietin and Medicare payment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980929-2

7 January 2021

Access to recombinant erythropoietin by Medicare-entitled dialysis patients in the first year after FDA approval

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980929-2

7 January 2021

Subcutaneous administration of recombinant human erythropoietin to subjects on continuous ambulatory peritoneal dialysis: an erythrokinetic assessment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2812%2980929-2

7 January 2021

10.1016/S0272-6386(12)80929-2

Identifiers

DOI

1 reference

25 February 2018

1 reference

25 February 2018